152 related articles for article (PubMed ID: 27241667)
1. Growth hormone receptor antagonism suppresses tumour regrowth after radiotherapy in an endometrial cancer xenograft model.
Evans A; Jamieson SM; Liu DX; Wilson WR; Perry JK
Cancer Lett; 2016 Aug; 379(1):117-23. PubMed ID: 27241667
[TBL] [Abstract][Full Text] [Related]
2. The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth.
Divisova J; Kuiatse I; Lazard Z; Weiss H; Vreeland F; Hadsell DL; Schiff R; Osborne CK; Lee AV
Breast Cancer Res Treat; 2006 Aug; 98(3):315-27. PubMed ID: 16541323
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice.
McCutcheon IE; Flyvbjerg A; Hill H; Li J; Bennett WF; Scarlett JA; Friend KE
J Neurosurg; 2001 Mar; 94(3):487-92. PubMed ID: 11235955
[TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: implications for cancer therapy.
Yin D; Vreeland F; Schaaf LJ; Millham R; Duncan BA; Sharma A
Clin Cancer Res; 2007 Feb; 13(3):1000-9. PubMed ID: 17289896
[TBL] [Abstract][Full Text] [Related]
5. Autocrine human GH promotes radioresistance in mammary and endometrial carcinoma cells.
Bougen NM; Steiner M; Pertziger M; Banerjee A; Brunet-Dunand SE; Zhu T; Lobie PE; Perry JK
Endocr Relat Cancer; 2012 Oct; 19(5):625-44. PubMed ID: 22807498
[TBL] [Abstract][Full Text] [Related]
6. Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly.
Jawiarczyk A; Kałuzny M; Bolanowski M; Bednarek-Tupikowska G
Neuro Endocrinol Lett; 2008 Aug; 29(4):571-6. PubMed ID: 18766168
[TBL] [Abstract][Full Text] [Related]
7. GH Action in Prostate Cancer Cells Promotes Proliferation, Limits Apoptosis, and Regulates Cancer-related Gene Expression.
Unterberger CJ; Maklakova VI; Lazar M; Arneson PD; Mcilwain SJ; Tsourkas PK; Hu R; Kopchick JJ; Swanson SM; Marker PC
Endocrinology; 2022 May; 163(5):. PubMed ID: 35383352
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of growth hormone (GH) action in mice: discovery of GH receptor antagonists and clinical indications.
Kopchick JJ; List EO; Kelder B; Gosney ES; Berryman DE
Mol Cell Endocrinol; 2014 Apr; 386(1-2):34-45. PubMed ID: 24035867
[TBL] [Abstract][Full Text] [Related]
9. Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient.
van der Lely AJ; Muller A; Janssen JA; Davis RJ; Zib KA; Scarlett JA; Lamberts SW
J Clin Endocrinol Metab; 2001 Feb; 86(2):478-81. PubMed ID: 11157994
[TBL] [Abstract][Full Text] [Related]
10. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist.
Jørgensen JO; Feldt-Rasmussen U; Frystyk J; Chen JW; Kristensen LØ; Hagen C; Ørskov H
J Clin Endocrinol Metab; 2005 Oct; 90(10):5627-31. PubMed ID: 16046586
[TBL] [Abstract][Full Text] [Related]
11. Growth hormone receptor antagonists.
Kohn DT; Kopchick JJ
Minerva Endocrinol; 2002 Dec; 27(4):287-98. PubMed ID: 12511851
[TBL] [Abstract][Full Text] [Related]
12. Growth hormone (GH) activity is associated with increased serum oestradiol and reduced anti-Müllerian hormone in healthy male volunteers treated with GH and a GH antagonist.
Andreassen M; Frystyk J; Faber J; Kristensen LØ; Juul A
Andrology; 2013 Jul; 1(4):595-601. PubMed ID: 23785020
[TBL] [Abstract][Full Text] [Related]
13. Growth Hormone differentially modulates chemoresistance in human endometrial adenocarcinoma cell lines.
Gentilin E; Minoia M; Bondanelli M; Tagliati F; Degli Uberti EC; Zatelli MC
Endocrine; 2017 Jun; 56(3):621-632. PubMed ID: 27585662
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.
Colao A; Pivonello R; Auriemma RS; De Martino MC; Bidlingmaier M; Briganti F; Tortora F; Burman P; Kourides IA; Strasburger CJ; Lombardi G
Eur J Endocrinol; 2006 Mar; 154(3):467-77. PubMed ID: 16498061
[TBL] [Abstract][Full Text] [Related]
15. Pegvisomant: current and potential novel therapeutic applications.
Thankamony GN; Dunger DB; Acerini CL
Expert Opin Biol Ther; 2009 Dec; 9(12):1553-63. PubMed ID: 19916734
[TBL] [Abstract][Full Text] [Related]
16. GH receptor blocker administration and muscle-tendon collagen synthesis in humans.
Nielsen RH; Doessing S; Goto K; Holm L; Reitelseder S; Agergaard J; Schjerling P; Flyvberg A; Kjaer M
Growth Horm IGF Res; 2011 Jun; 21(3):140-5. PubMed ID: 21498100
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant.
Sesmilo G; Fairfield WP; Katznelson L; Pulaski K; Freda PU; Bonert V; Dimaraki E; Stavrou S; Vance ML; Hayden D; Klibanski A
J Clin Endocrinol Metab; 2002 Apr; 87(4):1692-9. PubMed ID: 11932303
[TBL] [Abstract][Full Text] [Related]
18. Cancer and the potential place for growth hormone receptor antagonist therapy.
Friend KE
Growth Horm IGF Res; 2001 Jun; 11 Suppl A():S121-3. PubMed ID: 11527083
[TBL] [Abstract][Full Text] [Related]
19. Lowering total plasma insulin-like growth factor I concentrations by way of a novel, potent, and selective growth hormone (GH) receptor antagonist, pegvisomant (B2036-peg), augments the amplitude of GH secretory bursts and elevates basal/nonpulsatile GH release in healthy women and men.
Veldhuis JD; Bidlingmaier M; Anderson SM; Wu Z; Strasburger CJ
J Clin Endocrinol Metab; 2001 Jul; 86(7):3304-10. PubMed ID: 11443205
[TBL] [Abstract][Full Text] [Related]
20. Therapeutically blocking Interleukin-11 Receptor-α enhances doxorubicin cytotoxicity in high grade type I endometrioid tumours.
Winship A; Van Sinderen M; Rainczuk K; Dimitriadis E
Oncotarget; 2017 Apr; 8(14):22716-22729. PubMed ID: 28186993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
